Abstract
Growth of Streptococcus zooepidemicus in a 10 l bioreactor with 50 g sucrose/l and 10 g casein hydrolysate/l gave 5–6 g hyaluronic acid/l after 24–28 h. Purification of hyaluronic acid gave a recovery of 65% with the final material having an Mr of ∼4 × 106 Da with less than 0.1% protein.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Hyaluronic acid (HA) is a uniformly repetitive, linear glycosaminoglycan composed of 2,000–25,000 disaccharides of glucuronic acid and N-acetylglucosamine linked alternately by β-(1-3)- and β-(1-4)-glycosidic bonds. HA exists as a hydrated gel and is ubiquitous in human and animal tissues (Swann and Kuo 1991). It provides lubrication in the joints and serves as shock absorber. HA also plays important role in embryogenesis, signal transduction and cell motility and is associated with cancer invasiveness and metastasis (Kogan et al. 2007). Its distinctive viscoelastic properties, coupled with its lack of immunogenicity or toxicity, have led to a wide range of applications in the cosmetic and pharmaceutical industries, including skin moisturizers, osteo-arthritis treatment, ophthalmic surgery, adhesion prevention after abdominal surgery and wound healing (Goa and Benfield 1994; Laurent and Fraser 1992).
HA purified from a variety of sources has Mr values ranging from 104 to 107 Da (Shimada and Matsumura 1975). Many of the clinical applications of HA depend on its molecular size and there are several patents that focus on this aspect (Swann and Kuo 1991). Though HA is usually isolated from animals (Van Brunt 1986), there is an increasing demand for products from non-animal sources. Microbial HA production is now being investigated both for obtaining higher yield and quality, achieved through physiological and genetic manipulations. The most commonly used microbial strain for the production of HA belong to the Group A or C Streptococcus. Few studies have optimized the culture conditions for producing high molecular size HA in Streptococcus zooepidemicus (Johns et al. 1994; Armstrong and Johns 1997) and the majority of the literature has focused mainly on obtaining a highly pure product suitable for clinical applications. The present report describes the effect of carbon source and media composition on the Mr of HA. A novel and efficient purification process for high molecular size medical grade HA is the highlight of this report.
Materials and methods
Bacterial strain and media
Streptococcus equi subsp. zooepidemicus ATCC 39920 was grown in a medium constituting casein enzyme hydrolysate, 25 g/l; yeast extract, 3.5 g/l; K2HPO4, 2 g/l; NaCl, 1.5 g/l; MgSO4 · 7H2O, 0.4 g/l; and carbon source, 20 g/l; either in a 10 l bioreactor (Bioengineering L-1523). The fermentor was operated at 37°C at 400 rpm for 28 h at 2 vvm aeration. All experiments were carried out at least in triplicates to ensure reproducibility.
Estimation of HA
HA in the fermented broth was routinely estimated by the carbazole assay measuring uronic acid (Bitter and Muir 1962). To avoid interference in the assay by media components, the HA in the cell-free broth was precipitated with 2-propanol (1:1 v/v), re-dissolved in 3% (w/v) sodium acetate and then estimated. The assay detects the glucuronic acid released after the hydrolysis of HA with H2SO4.
Molecular size determination
The molecular size of HA was determined by size-exclusion chromatography on HPLC using a Shodex OH-Pak SB805-804HQ columns connected in series. The mobile phase used was 1 M NaNO3 at 1 ml/min. The eluate was monitored using an RI detector. The column was calibrated with pullulan standards (Shodex P-82) of varying molecular weights.
Purification of HA
The highly viscous fermented broth having 5 g HA/l or higher is diluted with equal volume of pyrogen-free water and centrifuged at 17686g for 20 min at 4°C for removal of cells. HA from the clarified broth was purified as described in Table 1.
Results and discussion
Distribution of HA of various molecular size during growth
As reported elsewhere (Armstrong and Johns 1997), the production of HA is a growth-associated phenomenon with the low Mr HA (∼5 kDa) appearing in the beginning (data not shown) followed by the accumulation of high Mr HA (>800 kDa) by the end of 22 h of fermentation. As lactose or sucrose in the medium gave HA of higher Mr (>800 kDa) as than glucose, all our subsequent experiments were carried out using sucrose as carbon source.
Effect of sucrose and casein enzyme hydrolyzate concentration on production of high molecular size HA
Increasing the sucrose concentration in the medium from 20 to 50 g/l with concomitant decrease in casein enzyme hydrolyzate from 25 to 10 g/l resulted in dramatic increase in the viscosity of the fermentation broth as a result of higher HA production (Table 2). These conditions favour a lower growth rate and higher production of HA resulting in a yield of over 5 g/l (Fig. 1). Unlike another report wherein lysozyme was added to the culture broth to increase the Mr to 3.8 × 106 Da (Kim et al. 1996), our process yields HA of Mr of about 3.5 × 106–3.9 × 106 Da in 24 h at 37°C, pH 7.0, 400 rpm and 2 vvm aeration without any major modification.
Purification of HA
Production and purification of high Mr HA that meets the specifications set for medical applications by the pharmacopeia has been a challenge and quality rather than quantity has been the focus of strain and process development in patents on HA production. The inherent viscosity of HA which increases with increase in Mr presents a major obstacle during fermentation as well as in purification. Fermentation parameters that balance the production of HA, which is inversely related to the growth, are crucial.
Several previous separation procedures have used multiple solvent precipitations, cationic detergent treatment, diafiltration, anion exchange resin treatment, protease digestion for purification of HA. Table 1 describes a novel purification process for HA that includes silica gel filtration combined with active carbon treatment followed by diafiltration. A single solvent precipitation step is used which drastically reduces the solvent usage unlike other processes (Brown et al. 1994; Han et al. 2004). Removal of protein impurities by 96% is achieved through treatment with silica gel and active carbon rather than detergents which necessitate multiple washes post-treatment (Nimrod et al. 1988; Brown et al. 1994). Ultrafiltration in the diafiltration mode further removes the impurities yielding a product with 0.06% protein with respect to HA. Although diafiltration has been used in other reports (Carlino and Magnette 2002), our process is more efficient involving very low dilution with solvent and yielding a better quality of HA. A final 0.22 μm filtration step renders the product sterile with a yield of 65%. The quality of HA obtained complies with the specifications of British Pharmacopeia (BP 2003) for medical grade HA (Table 3). Thus, the present process described is simple, economical and reproducible giving high yield of medical grade high Mr HA.
References
Armstrong D, Johns MR (1997) Culture conditions affect the molecular weight properties of hyaluronic acid produced by Streptococcus zooepidemicus. Appl Environ Microbiol 63:2759–2764
Bitter T, Muir M (1962) A modified uronic acid carbazole reaction. Anal Biochem 4:330–334
British Pharmacopeia (2003)
Brown KK, Ruiz LLC, van de Rijn I et al (1994) Method for the microbiological production of non-antigenic hyaluronic acid. US Patent 5,316,926, 31 May 1994
Carlino S, Magnette F (2002) Process for purifying high molecular weight hyaluronic acid. US Patent 6,489,467 B1, 3 Dec 2002
Goa KL, Benfield P (1994) Hyaluronic acid: a review of its pharmacology and use as a surgical aid in ophthalmology and its therapeutic potential in joint disease and would healing. Drugs 47:536–566
Han HY, Jang SH, Kim EC et al (2004) Microorganism producing hyaluronic acid and purification method of hyaluronic acid. WO 2004/016771, 26 Feb 2004
Johns MR, Goh LT, Oeggerli A (1994) Effect of pH, agitation and aeration on hyaluronic acid production by Streptococcus zooepidemicus. Biotechnol Lett 16:507–512
Kim JH, Yoo SJ, Oh DK et al (1996) Selection of a Streptococci equi mutant and optimization of culture conditions for the production of high molecular weight hyaluronic acid. Enzyme Microb Technol 19:440–445
Kogan G, Ŝoltés L, Stern R et al (2007) Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett 29:17–25
Laurent CT, Fraser JRE (1992) Hyaluronan. FASEB J 6:2397–2404
Nimrod A, Benjamin G, Dov K et al (1988) High molecular weight sodium hyaluronate. US Patent 4,784,990, 15 Nov 1988
Shimada E, Matsumura G (1975) Viscosity and molecular weight of hyaluronic acids. J Biochem 78:513–517
Swann DA, Kuo JW (1991) Hyaluronic acid. In: Byrom D (ed) Biomaterials-novel materials from biological sources. Stockton Press, New York, pp 286–305
Van Brunt J (1986) More to hyaluronic acid than meets the eye. Bio/Technology 156:1059–1065
Acknowledgements
The authors gratefully acknowledge the encouragement and support of Reliance Life Sciences Pvt. Ltd., in carrying out the research work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rangaswamy, V., Jain, D. An efficient process for production and purification of hyaluronic acid from Streptococcus equi subsp. zooepidemicus . Biotechnol Lett 30, 493–496 (2008). https://doi.org/10.1007/s10529-007-9562-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10529-007-9562-8